- Report
- July 2025
- 150 Pages
Global
From €5223EUR$5,950USD£4,544GBP
- Report
- January 2026
- 191 Pages
Global
From €3458EUR$3,939USD£3,008GBP
- Report
- February 2026
- 281 Pages
Global
From €5135EUR$5,850USD£4,467GBP
- Report
- February 2026
- 364 Pages
Global
From €5135EUR$5,850USD£4,467GBP
- Report
- October 2025
- 250 Pages
Global
From €3941EUR$4,490USD£3,429GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1756EUR$2,000USD£1,527GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1097EUR$1,250USD£955GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €2194EUR$2,500USD£1,909GBP
- Report
- April 2025
- 183 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- October 2025
- 150 Pages
Global
From €3379EUR$3,850USD£2,940GBP
€4257EUR$4,850USD£3,704GBP
- Report
- August 2025
- 120 Pages
United States
From €3467EUR$3,950USD£3,017GBP
- Report
- November 2018
- 147 Pages
Global
From €2414EUR$2,750USD£2,100GBP
- Report
- December 2024
- 150 Pages
Global
From €5223EUR$5,950USD£4,544GBP
- Report
- October 2023
- 145 Pages
Global
From €2765EUR$3,150USD£2,406GBP
- Report
- October 2023
- 145 Pages
Global
From €2765EUR$3,150USD£2,406GBP
- Report
- December 2024
- 84 Pages
Global
From €3467EUR$3,950USD£3,017GBP
- Report
- February 2024
- 168 Pages
Global
From €6978EUR$7,950USD£6,071GBP
- Report
- July 2023
- 135 Pages
Global
From €6583EUR$7,500USD£5,728GBP
- Report
- July 2023
- 67 Pages
Global
From €3467EUR$3,950USD£3,017GBP
- Report
- November 2023
- 189 Pages
Global
From €3950EUR$4,500USD£3,437GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more